ECSP003683A - RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS - Google Patents
RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODSInfo
- Publication number
- ECSP003683A ECSP003683A ECSP003683A ECSP003683A EC SP003683 A ECSP003683 A EC SP003683A EC SP003683 A ECSP003683 A EC SP003683A EC SP003683 A ECSP003683 A EC SP003683A
- Authority
- EC
- Ecuador
- Prior art keywords
- peptides
- insulin
- pituitary
- cycling
- use methods
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000001351 cycling effect Effects 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 230000001817 pituitary effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 230000003914 insulin secretion Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Esta invención presenta novedosos péptidos que funcionan in vivo para estimular la libreación de insulina de las célñulas beta pancráticas en forma dependiente de la glucosa. Se ha demostrado que estos peptidos secretagogos de insulina estimulan la liberación de insulina en las células de islotes de ratas in vitro e in vivo. Los péptidos de la presente invención proporcionan una nueva terapia para pacientes con secreción de insulina disminuida, en especial diabéticos de tipo 2. En especial, la invención es un polipéptido seleccionado entre un grupo especifico de polipéptidos relacionados con VIP/PACAP, o equivalentes funcionales del mismo. La invención se refiere asi mismo a un método para tratar una enfermedad metabólica en un mamifero que comprende administrar una cantidad terapéuticamente efectiva de los péptidos secretagogos de insulina a dicho mamífero. También se describen métodos para preparar los péptidos, tanto recombinantes como sintéticos.This invention features novel peptides that work in vivo to stimulate insulin release from pancreatic beta cells in a glucose-dependent manner. These insulin secretagogue peptides have been shown to stimulate the release of insulin in rat islet cells in vitro and in vivo. The peptides of the present invention provide a new therapy for patients with decreased insulin secretion, especially type 2 diabetics. In particular, the invention is a polypeptide selected from a specific group of VIP / PACAP-related polypeptides, or functional equivalents of the same. The invention also relates to a method for treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of insulin secretagogue peptides to said mammal. Methods for preparing both recombinant and synthetic peptides are also described.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003683 ECSP003683A (en) | 2000-09-28 | 2000-09-28 | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP003683 ECSP003683A (en) | 2000-09-28 | 2000-09-28 | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP003683A true ECSP003683A (en) | 2001-09-24 |
Family
ID=42041274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP003683 ECSP003683A (en) | 2000-09-28 | 2000-09-28 | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP003683A (en) |
-
2000
- 2000-09-28 EC ECSP003683 patent/ECSP003683A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2000000071A (en) | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS | |
| UY27893A1 (en) | AGONISTS OF THE RECEIVER (VPAC2) OF THE ACTIVATING PEPTIDE OF THE HYPOFISARY ADENYLATOCICLASS (PACAP) AND ITS PHARMACOLOGICAL USE METHODS | |
| Crawley et al. | Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus | |
| JP3262329B2 (en) | GLP-1 analog useful for the treatment of diabetes | |
| ATE139540T1 (en) | MEDICINAL PEPTIDES | |
| RU2001136014A (en) | RECEPTOR-3 (R3) AGONISTS OF THE PEPTIDE ACTIVATOR OF THE PITUITARY ADENYLATICLICASE (RASAR) AND METHODS OF THEIR PHARMACOLOGICAL APPLICATION | |
| US20130195807A1 (en) | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets | |
| DOP2002000475A (en) | PEPTIDES THAT ACT AS GLON-RECEPTOR AGONISTS AND AS GLUCAGON RECEIVER ANTAGONISTS AND THEIR METHODS OF PHARMACOLOGICAL USE | |
| WO2006121860A3 (en) | Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use | |
| Dockray et al. | Relations between neuropeptides and gut hormones | |
| IE861004L (en) | Octapeptides | |
| ES2207656T3 (en) | ANTAGONISTS OF NEUROMEDINA B RECEPTORS B. | |
| BR0305039A (en) | Use of compounds that possess the biological activity of intestinal vasoactive peptide for the treatment of sarcoidosis. | |
| Polak | Regulatory peptides | |
| AR025902A1 (en) | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS | |
| PE20030608A1 (en) | COMPOSITION AND METHOD TO TREAT DIABETES | |
| BRPI0507177A (en) | (vpac2) agonists of the pituitary adenylate cyclase activation peptide receptor (pacap) and their pharmacological methods of use | |
| Markoff et al. | Effects of prolactin and glycosylated prolactin on (pro) insulin synthesis and insulin release from cultured rat pancreatic islets | |
| AR053263A1 (en) | RECEPTOR AGONISTS (VPAC2) OF PEPTIDE ACTIVATOR OF HYPOFISARY CYCLASS ADENYLATE (PACAP) AND ITS PHARMACOLOGICAL USE METHODS | |
| Gargosky et al. | C-terminal bombesin sequence requirements for binding and effects on protein synthesis in Swiss 3T3 cells | |
| Rivier et al. | Somatostatin receptor 1 selective analogues: 3. Dicyclic peptides | |
| Gaudillere et al. | Huan normal dermal fibroblasts express somatostain receptors | |
| TAMINATO et al. | Bombesin inhibits insulin release from isolated pancreatic islets of rats in vitro | |
| Wisner et al. | [D-Ala1, Leu9-ψ-CH2NH-Leu0] Neuromedin C Antagonizes Neuromedin C-Stimulated Amylase Release by Acini Isolated from the Rat Pancreas | |
| Habener | The role of pancreatic duodenum homeobox protein-1 in the development of diabetes mellitus |